Frishullo et al. reported that T cells and monocytes obtained from MS patients during relapse had higher levels of activated STAT3 and lower levels of SOCS3 than comparable cells from patients in remission42, 50. This evidence concerns the gene STAT3 and myeloid sarcoma.